Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.

Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2.

Publication date: Jan 20, 2024

The immune responses to Novavax’s licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-M adjuvanted vaccines predominantly elicits immune events in local tissues with little spillover to the periphery. A third dose of an updated vaccine based on the Gamma (P. 1) variant 7 months after two immunizations with licensed NVX-CoV2373 resulted in significant enhancement of anti-spike antibody titers and antibody breadth including neutralization of forward drift Omicron variants. The third immunization expanded the Spike-specific memory B cell pool, induced significant somatic hypermutation, and increased serum antibody avidity, indicating considerable affinity maturation. Seven months after immunization, vaccinated animals controlled infection by either WA-1 or P. 1 strain, mediated by rapid anamnestic antibody and T cell responses in the lungs. In conclusion, a third immunization with an adjuvanted, low-dose recombinant protein vaccine significantly improved the quality of B cell responses, enhanced antibody breadth, and provided durable protection against SARS-CoV-2 challenge.

Open Access PDF

Concepts Keywords
Improved Antibody
Macaques Breadth
Nanoparticle Cov
Pool Durable
Vaccines Immune
Immunization
Immunizations
Licensed
Novavax
Nvx
Protection
Sars
Spike
Vaccine
Vaccines

Semantics

Type Source Name
disease VO NVX-CoV2373
disease VO vaccine
disease VO immunization
disease VO dose
disease IDO cell
disease VO vaccinated
disease MESH infection
disease IDO quality
disease VO subunit vaccine
disease MESH COVID 19
drug DRUGBANK Histamine
disease IDO production
disease IDO immune response
disease VO frequency
disease VO vaccination
disease VO immunized
disease MESH Allergy
disease MESH Tumor
disease MESH Infectious Diseases
disease VO USA
disease MESH Bacterial diseases
drug DRUGBANK Coenzyme M
disease VO injection
disease IDO blood
disease IDO site
disease IDO assay
drug DRUGBANK Dimercaprol
disease VO titer
drug DRUGBANK Aspartame

Original Article

(Visited 1 times, 1 visits today)